Navigation Links
Memory Pharmaceuticals Receives NASDAQ Decisions
Date:12/3/2008

mpletion of the Review Council's review, the Company's securities will continue to be listed on NASDAQ.

About the Company

Memory Pharmaceuticals Corp., a biopharmaceutical company, is focused on developing innovative drugs for the treatment of debilitating CNS disorders, many of which exhibit significant impairment of memory and other cognitive functions, including Alzheimer's disease and schizophrenia. For additional information, please visit our website at http://www.memorypharma.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or Memory Pharmaceuticals' prospects, future financial position, future revenues and projected costs should be considered forward-looking. Readers are cautioned that actual results may differ materially from projections or estimates due to a variety of important factors, including the outcome of clinical trials of Memory Pharmaceuticals' drug candidates and whether they demonstrate these candidates' safety and effectiveness; the risks and uncertainties associated with: the possibility that the Company's acquisition by Roche will not be completed, obtaining additional financing to support Memory Pharmaceuticals' R&D and clinical activities and operations; obtaining regulatory approvals to conduct clinical trials and to commercialize Memory Pharmaceuticals' drug candidates; Memory Pharmaceuticals' ability to enter into and maintain collaborations with third parties for its drug development programs; Memory Pharmaceuticals' dependence on its collaborations and its license relationships; achieving milestones under Memory Pharmaceuticals' col
'/>"/>

SOURCE Memory Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
2. Removing Ovaries Before Menopause Leads to Memory, Movement Troubles
3. Boston University School of Medicine researcher recipient of Memory Ride Grant
4. New understanding of basic units of memory
5. Obesity Wont Affect Seniors Memory
6. HRT: A Boost for Libido, But Not Memory
7. Memory tasks require more coordinated brain blood flow for people with high blood pressure
8. Computerized training of working memory is a promising therapeutic strategy in ADHD
9. Alzheimers Foundation of America Holds Fifth Annual National Memory Screening Day
10. Survey Reveals Widespread Lack of Communication With Doctors About Memory Concerns
11. Memory Pharmaceuticals to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:CoorsTek Holds Grand Opening for Newest Facility in South Korea 2Health News:CoorsTek Holds Grand Opening for Newest Facility in South Korea 3Health News:Don't Wait for the Election to Plan Your Long-Term Healthcare, Insurance Leader Advises 2Health News:Chemo for Mesothelioma Offers Limited Survival Benefits 2Health News:dLife Launches the World's Largest and Most Comprehensive Online Food and Diabetic Recipe Search Tool 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 2Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 3Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 4Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 5Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 6Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 7Health News:Pharmasset Reports Financial Results for Quarter Ended March 31, 2008 8
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Express Scripts Launches Equity Offering to Finance Acquisition 47588 1Express Scripts Launches Equity Offering to Finance Acquisition 47588 2Express Scripts Launches Equity Offering to Finance Acquisition 47588 3Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 1Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 2Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 3Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 4Leading North American Emergency Medical Services Provider British Columbia Ambulance Service Selects NICE Inform for Improved Service 12409 5Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 1Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 2Prometheus Announces New Findings Regarding Patients at Risk for Celiac Disease at DDW 4513 3
Other Medicine Technology:Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 2Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 3Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 4Orchestra Therapeutics Announces New Phase II Clinical Data on,NeuroVax Demonstrating Marked Expansion of Regulatory T Cell,Populations in Patients With Multiple Sclerosis 5Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 2Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 3Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 4Fractionated Radioimmunotherapy With (90)Y-epratuzumab in,Non-Hodgkin's Lymphoma Appears Safe and Active in a Phase I/II,Study 5